Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shaanxi Micot Pharmaceutical Technology Co., Ltd.
陝西麥科奧特醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02335)

ANNOUNCEMENT IN RELATION TO THE POSTPONEMENT OF THE EGM AND CHANGE OF BOOK CLOSURE PERIOD

References are made to the notice (the "**Notice**") and the circular (the "**Circular**") of the extraordinary general meeting (the "**EGM**") of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (the "**Company**") both dated 22 October 2026. Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Circular.

POSTPONEMENT OF THE EGM

In order to give the Shareholders sufficient time to consider the resolution to be proposed at the EGM and take actions, the Board hereby announces that the EGM, which was initially scheduled to be held at 10:00 a.m. on Tuesday, 10 November 2026 as set out in the Notice, will be rescheduled to 10:00 a.m. on Friday, 20 November 2026 (the "**Postponed EGM**"). The venue of the Postponed EGM will remain unchanged.

As stated in the Circular and the Notice, the register of members of the Company was originally scheduled to be closed from Thursday, 5 November 2026 to Tuesday, 10 November 2026 (both days inclusive). Following the postponement of the EGM, the last day for closure of the register of members of the Company will be extended from Tuesday, 10 November 2026 to Friday, 20 November 2026 (the last day inclusive). Holders of H Shares and Unlisted Shares whose names appear on the register of members of the Company on Friday, 20 November 2026 will be entitled to attend and vote at the Postponed EGM in respect of the resolution to be proposed thereat. The locations for lodging all transfers accompanied by the relevant certificates remain unchanged as set out in the Circular and the Notice.

PROXY FORMS

The resolution as set out in the Notice will remain unchanged for the Postponed EGM. The form of proxy for the EGM dated 22 October 2026 (the "**Proxy**"), together with the Circular and the Notice, will remain valid for the Postponed EGM.

Shareholders who have not yet returned the Proxy but intend to appoint a proxy to attend the Postponed EGM are required to return the Proxy, together with the power of attorney or other authority (if any) under which it is signed, or a notarially certified copy thereof, to the Company's H Share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for H Shareholders), or the Company's registered office in the PRC at Room B06, 26th Floor, Building 5, Digital China Science and Technology Park, No. 20, Zhangba 4th Road, High-tech Development Zone, Xi'an, Shaanxi Province, PRC (for Unlisted Shareholders), as soon as possible but in any event not less than 24 hours before the time appointed for the holding of the Postponed EGM (i.e. not later than 10:00 a.m. on Thursday, 19 November 2026) or any adjournment thereof.

If a Shareholder has already completed and returned the Proxy in accordance with the instructions printed thereon, such Proxy will remain valid for the Postponed EGM and such Shareholder is not required to re-submit the Proxy.

The Board confirms that the abovementioned changes do not affect other information contained in the Circular, the Notice and the Proxy. Save for the abovementioned changes, all other information in the Circular, the Notice and the Proxy remain unchanged.

By order of the Board
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Dr. Wang Bing
Chairman, Chief Executive Officer and Executive Director

Xi'an, Shaanxi, the PRC, 6 November 2026

As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as independent non-executive Directors.